Maica Galán

706 total citations
29 papers, 395 citations indexed

About

Maica Galán is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Maica Galán has authored 29 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 16 papers in Surgery and 11 papers in Oncology. Recurrent topics in Maica Galán's work include Gastric Cancer Management and Outcomes (16 papers), Esophageal and GI Pathology (9 papers) and Esophageal Cancer Research and Treatment (8 papers). Maica Galán is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Esophageal and GI Pathology (9 papers) and Esophageal Cancer Research and Treatment (8 papers). Maica Galán collaborates with scholars based in Spain and Palestinian Territory. Maica Galán's co-authors include M. Morell, Núria Sala, M. Calvo, Ramón Salazar, Leandre Farràn, Berta Laquente, A Rafecas, Enrique Aranda, Fernando Rivera and Josep R. Germà and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Maica Galán

26 papers receiving 389 citations

Peers

Countries citing papers authored by Maica Galán

Since Specialization

Citations

This map shows the geographic impact of Maica Galán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maica Galán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maica Galán more than expected).

Fields of papers citing papers by Maica Galán

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maica Galán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maica Galán. The network helps show where Maica Galán may publish in the future.

Co-authorship network of co-authors of Maica Galán

This figure shows the co-authorship network connecting the top 25 collaborators of Maica Galán. A scholar is included among the top collaborators of Maica Galán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maica Galán. Maica Galán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3PC-030 Design and development of a magistral formulation of mouthwash for the treatment of mucositis: a case report 2025 ·Maica Galán, Antonio López Gómez, (unknown), (unknown), (unknown), (unknown)	0
2	Half of the patients with subepithelial tumours present borderline or pathologic anxiety-distress and carcinophobia: multicentre cohort study 2022 ·Revista Española de Enfermedades Digestivas ·(unknown), Anna Casellas‐Grau, Sebastián Videla, Carme Loras, (unknown), Francisco Gil, Maica Galán, Fernando Fernández‐Aranda, (unknown), Joan B. Gornals	1
3	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial 2021 ·European Journal of Cancer ·Fernando Rivera, (unknown), Pilar García‐Alfonso, Eva Martínez de Castro, Javier Gállego, María Luisa Limón, María Alsina, L. López, Maica Galán, E. Falcó, José Luís Zamora Manzano, Encarnación González‐Flores, (unknown), Carlos López, Enrique Aranda, (unknown), (unknown), Paula Jiménez‐Fonseca	43
4	Comparison and applicability of molecular classifications for gastric cancer 2019 ·Cancer Treatment Reviews ·(unknown), Maica Galán, M. Morell, M. Calvo, Núria Sala, Ramón Salazar	61
5	¿Puede el acondicionamiento gástrico disminuir la incidencia de dehiscencia anastomótica esofagogástrica cervical? 2018 ·Cirugía Española ·(unknown), Leandre Farràn, (unknown), (unknown), (unknown), (unknown), Carla Bettónica, Maica Galán	3
6	Does Gastric Conditioning Decrease the Incidence of Cervical Oesophagogastric Anastomotic Leakage? 2018 ·Cirugía Española (English Edition) ·(unknown), Leandre Farràn, (unknown), (unknown), (unknown), (unknown), Carla Bettónica, Maica Galán	3
7	Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre 2017 ·PLoS ONE ·Maria Saigí, Marc Oliva, Luisa Aliste, Mariona Calvo, (unknown), (unknown), (unknown), Leandre Farràn, (unknown), (unknown), María José Paúles, Joan B. Gornals, Eugenia De Lama, Josep M. Borràs, Núria Sala, Maica Galán	6
8	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients 2017 ·Targeted Oncology ·(unknown), María Alsina, Fernando Rivera, Francisco Javier Ramos, Maica Galán, Rafael López‐López, Pilar García‐Alfonso, José E. Alés‐Martínez, Bernardo Queralt, Antonio Antón, Alfredo Carrato, Cristina Grávalos, María José Méndez-Vidal, Carlos López, (unknown), Josep Tabernero, J. Giralt, Enrique Aranda	1
9	Endoscopic band ligation without resection in selected patients for small and superficial upper gastrointestinal tract lesions 2016 ·Revista Española de Enfermedades Digestivas ·Gemma Ibáñez‐Sanz, Joan B. Gornals, (unknown), Sílvia Salord, María José Paúles, (unknown), Maica Galán	3
10	Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study 2014 ·Clinical & Translational Oncology ·Maica Galán, Leandre Farràn, Luisa Aliste, (unknown), (unknown), Carla Bettónica, (unknown), (unknown), M. Calvo, (unknown), (unknown), Joan B. Gornals, Richard Mast, (unknown), María José Paúles, Juvencio Robles, N. Virgili, Josep M. Borràs	7
11	Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02. 2013 ·Journal of Clinical Oncology ·Fernando Rivera, Bartomeu Massutí, (unknown), Javier Sastre, Joaquina Martínez-Galán, Manuel Valladares‐Ayerbes, Raquel Serrano, (unknown), Josep Tabernero, Maica Galán, José Luis Manzano Mozo, Eduardo Díaz‐Rubio, (unknown), Margarita Reboredo, Silvia Vázquez, L. Layos Romero, (unknown), Enrique Aranda	1
12	NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis. 2013 ·Journal of Clinical Oncology ·Fernando Rivera, (unknown), Pilar Alfonso, Carlos López, Javier Gállego, María Luisa Limón, María Alsina, Luis López‐Gómez, Maica Galán, E. Falcó, José Luís Zamora Manzano, Encarnación González‐Flores, Raquel Serrano, (unknown), (unknown)	13
13	Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study) 2011 ·Annals of Oncology ·Enrique Aranda, (unknown), Fernando Rivera, Maica Galán, Manuel Valladares‐Ayerbes, Carles Pericay, (unknown), (unknown), Antonio Irigoyen López, A. Arriví, Javier Sastre, Eduardo Díaz‐Rubio	36
14	Preoperative gastric conditioning in cervical gastroplasty 2010 ·Diseases of the Esophagus ·Leandre Farràn, (unknown), Esther Alba, Carla Bettónica, (unknown), Maica Galán, A Rafecas	22
15	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma 2010 ·Cancer Chemotherapy and Pharmacology ·(unknown), Fernando Rivera, Maica Galán, Josep Tabernero, Andrés Cervantes, (unknown), Javier Gállego, (unknown), (unknown), Alfredo Carrato, P. Escudero, Bartomeu Massutí, Vicente Alonso-Orduña, (unknown), A. Sáenz, J. Giralt, (unknown), Antonio Antón, Enrique Aranda	2
16	Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases 2010 ·Cirugía Española (English Edition) ·Juan Fabregat, Juli Busquets, Núria Peláez, Rosa Jorba, Francisco Garcia‐Borobia, Cristina Masuet‐Aumatell, Carlos Valls, (unknown), Teresa Serrano, Maica Galán, (unknown), Berta Laquente, Emilio Ramos, Antoni Rafecas	1
17	Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma 2009 ·International Journal of Radiation OncologyBiologyPhysics ·Fernando Rivera, Maica Galán, Josep Tabernero, Andrés Cervantes, M. E. Vega-Villegas, Javier Gállego, (unknown), (unknown), Alfredo Carrato, P. Escudero, Bartomeu Massutí, Vicente Alonso-Orduña, (unknown), A. Sáenz, J. Giralt, (unknown), Antonio Antón, Enrique Aranda	31
18	Efficacy of enteral decontamination in the prevention of anastomotic dehiscence and pulmonary infection in esophagogastric surgery 2007 ·Diseases of the Esophagus ·Leandre Farràn, J. M. Llop Talaverón, (unknown), Esther Kreisler, (unknown), Maica Galán, A Rafecas	28
19	The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity 2007 ·Clinical & Translational Oncology ·Margarita Majem, Maica Galán, (unknown), Montserrat Muñoz-Mateu, (unknown), (unknown), M. Navarro, (unknown), Xavier García del Muro, E. Dotor, Berta Laquente, Josep R. Germà	20
20	[The teaching health centers of Barcelona. The opinions of residents]. 1993 ·PubMed ·Jacobo Sellarés, Maica Galán, (unknown), (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact